Cero Therapeutics Holdings Inc. (Nasdaq: CERO) announced a one-for-twenty reverse stock split of its common stock, effective June 13, 2025. As a result, the number of outstanding shares will be reduced from approximately 10.3 million to about 516,092. The stock will trade on a split-adjusted basis on the Nasdaq Capital Market. Proportional adjustments will also be made to equity incentive plans, stock options, preferred stock, and warrants.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.